Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Top 4 Largest Lithium Reserves by Country (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Trending Press Releases

Radiopharm achieves Nasdaq listing of ADS

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States

First Helium Confirms Plans for Sequential Drilling of Two Oil Targets - Proven Undeveloped Oil Location and Large Leduc Anomaly

CHARBONE Hydrogen Announces a First Closing of its $1M Non-Brokered Private Placement

Silver47 Drills 2.66 Metres of 1,801 g/t Silver Equivalent within 22.3 Metres of 601 g/t Silver Equivalent at its Red Mountain Project, Alaska

More Press Releases
Trending Companies

First Helium

HELI:CA

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA

Black Swan Graphene

SWAN:CC
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Graphite Outlook Report

2024 Lithium Market Outlook

2024 Uranium Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Exelixis Inc.

NASDAQ:EXEL
Press Releases

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

Exelixis Announces New Recommendations for CABOMETYX (Cabozantinib) Tablets

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Interactive Chart

×